Britain's communities secretary James Brokenshire embarked on a three-day visit to India on Thursday (4) to promote business and technology ties of the country with the Midlands region of England.
The UK Cabinet minister, who is also the British government's “Midlands Engine Champion”, is set to bring together senior British and Indian officials and businesses to re-affirm a post-Brexit commitment to the Midlands-Maharashtra Technology Partnership.
“The Midlands and Maharashtra are thriving tech hubs in their own right, and by bringing these two great regions together we are strengthening our technological and economic ties to the benefit of our people and businesses,” Brokenshire said in a statement.
“Whether it’s manufacturing the latest car model or sharing ground-breaking research, there is a lot to be gained and I’m determined we make the most of the opportunities, particularly as we prepare to leave the European Union,” he said.
The Midlands-Maharashtra Technology Partnership has been described by the UK government as the regional element of the UK-India Technology Partnership announced by India prime minister Narendra Modi and his British counterpart Theresa May during his visit to the UK in April.
The Indian and British governments had committed to increasing partnerships in technology through the industry, government, science and research, and by fostering trade and investment opportunities in both directions.
Brokenshire will begin his engagements in New Delhi by holding talks with finance minister Arun Jaitley, Anant G Geete, minister for heavy industries and public sector enterprises, as well as Sir Dominic Asquith, British high commissioner to India.
In Maharashtra, the minister will hold talks with Indian advanced manufacturing giant Bharat Forge. He is joined on the Indian trade mission this week by the Mayor of the West Midlands, Andy Street, and Chair of the Midlands Engine partnership, Sir John Peace.
The UK government is also using the opportunity to encourage British companies to participate in the India-UK Future Tech Festival in New Delhi in December. The festival is being pitched as a thought-leadership summit which will bring together business, policy makers, venture capital, scientists and entrepreneurs.
It will drive trade, investment and partnerships across key sectors, and promote and celebrate the UK and India as major technology innovators and trading partners, the UK government said.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.